What is the VAP Cholesterol Test? A comprehensive lipoprotein analysis to improve patient diagnosis and treatment. The VAP cholesterol test provides a more comprehensive coronary heart disease (CHD) risk assessment than the conventional lipoprotein profile.

 

Unlike the conventional lipoprotein profile, the VAP cholesterol test measures all primary and secondary targets of therapy and the new emerging lipid risk factors identified by the NCEP ATP III* guidelines. Direct measurements, not estimations, are provided for total cholesterol, LDL, HDL, VLDL, and cholesterol subclasses.

 

A better, more efficient cholesterol test for patients at risk for coronary heart disease In a single test profile additional lipoprotein information is provided to assist physicians expand risk stratification for CHD and to develop patient-specific treatment initiatives. Lipoprotein response to treatment can vary; the additional information provided by the VAP cholesterol test, when medically indicated, can be helpful in selecting the most appropriate therapy, including choice of drugs and the intensity of risk-reduction therapy.

 

Meeting NCEP Guidelines by Identifying Primary and Secondary Targets of Therapy The VAP cholesterol test includes all serum lipids that define the targets of therapy recommended by ATP III: LDL cholesterol-Primary Target HDL cholesterol Total VLDL cholesterol Triglycerides Secondary Targets Non-HDL cholesterol-If triglycerides > 200 mg/dL Metabolic syndrome-triglycerides > 150 mg/dL and HDL cholesterol <40 mg/dL in men or <50 mg/dL in women.

 

More than a conventional lipoprotein profile - emerging risk factors measured: To enhance assessment of coronary heart disease risk, the VAP cholesterol test provides additional information measuring other lipids identified as emerging risk factors by ATP III. Lipoprotein(a) cholesterol Remnant lipoproteins Intermediate-density lipoprotein (IDL) cholesterol VLDL3 (small dense) cholesterol VLDL1+2 (large buoyant) cholesterol LDL particle density pattern (small dense vs large buoyant) Metabolic Syndrome Measurement of lipid components associated with the metabolic syndrome.

 

The ATP III emphasized the significant CHD risk associated with metabolic syndrome by designating it as a secondary target of risk-reduction therapy. (Metabolic syndrome is associated with greatly increased risk for type 2 diabetes and CHD.) The VAP profile identifies the lipid factors associated with metabolic syndrome-elevated triglycerides, low HDL-C, and increased levels of small dense LDL particles. Each VAP test is monitored for probable metabolic syndrome and flagged when indicated.

Quantity: